The country manager for CSL Behring Czech Republic reviews his tremendous success in the country, averaging 50 percent annual growth since 2011. Furthermore, he explains why the current reimbursement system is beneficial for them although it results in high price pressure for innovative pharmaceutical treatments.
The question on everybody’s lips is what gains market access first; Idelvion from CSL Behring or Alprolix from SOBI? At what stage does Idelvion currently stand in the Czech Republic?
The predictability induced by the system’s transparency typically allows us to be among the first of our European peers to introduce innovative treatments.
